Literature DB >> 25362075

Evaluation of vancomycin dosing and corresponding drug concentrations in pediatric patients.

Lauren Maurer Geerlof1, Jenny Boucher2.   

Abstract

OBJECTIVE: To describe the relationships between dosing strategy, age, and vancomycin trough concentrations in pediatric patients.
METHODS: This is a retrospective review of hospitalized pediatric patients between 2 months and 17 years of age treated with intravenous vancomycin from 2008 to 2011. The primary outcome was the number of patients achieving a target trough concentration of 10 to 20 μg/mL in each age group and dosing group. The secondary outcomes were the number of patients in each group to achieve a trough concentration of 15 to 20 μg/mL and the incidence of vancomycin-induced nephrotoxicity.
RESULTS: A total of 102 patients were included in the analysis. Forty-six of 159 evaluated troughs (28.9%) were within the target range of 10 to 20 μg/mL. Dose was found to have a statistically significant effect on the ability to achieve a trough within the target range (P = .01). Of the 159 trough concentrations evaluated, only 11 (6.9%) were within the range of 15 to 20 μg/mL. Nephrotoxicity occurred in 7 patients and was not associated with supratherapeutic trough concentration or dose.
CONCLUSIONS: The number of trough concentrations within the target range of 10 to 20 μg/mL was low, and younger patients often needed doses >60 mg/kg per day to achieve a trough concentration in this range. The dose of vancomycin was found to have a statistically significant effect on the ability to achieve a trough concentration within the target range.
Copyright © 2014 by the American Academy of Pediatrics.

Entities:  

Keywords:  MRSA; Staphylococcus aureus; antibiotic; child; children; infant; methicillin-resistant; pediatric; pharmacodynamics; pharmacokinetic; serum concentration; trough; vancomycin

Year:  2014        PMID: 25362075     DOI: 10.1542/hpeds.2014-0019

Source DB:  PubMed          Journal:  Hosp Pediatr        ISSN: 2154-1671


  7 in total

Review 1.  Treatment of Methicillin-Resistant Staphylococcus aureus (MRSA) Infections in Children: a Reappraisal of Vancomycin.

Authors:  Roopali Sharma; Margaret R Hammerschlag
Journal:  Curr Infect Dis Rep       Date:  2019-09-05       Impact factor: 3.725

2.  Risk Factors for Non-Therapeutic Initial Steady-State Vancomycin Trough Concentrations in Children and Adolescents Receiving High Empiric Doses of Intravenous Vancomycin.

Authors:  Whitney R Buckel; Shahira Ghobrial; Pranita D Tamma; Aaron M Milstone; Yuan Zhao; Alice J Hsu
Journal:  Paediatr Drugs       Date:  2017-02       Impact factor: 3.022

3.  Impact of the Implementation of a Vancomycin Protocol on Trough Serum Vancomycin Concentrations in a Pediatric Intensive Care Unit.

Authors:  Raíssa Queiroz Rezende; Cícero Armídio Gomes Dias; Claudia Pires Ricachinevsky; João Paulo de Lucena Capelari
Journal:  Paediatr Drugs       Date:  2021-04-08       Impact factor: 3.022

4.  Vancomycin dosing required to achieve a therapeutic level in children post-surgical correction of congenital heart disease.

Authors:  Yousif S Alakeel; Ghadah A Alanazi; Bushra S Alawbathani; Kadi I Alshutwi; Yazeed S Alahmed
Journal:  Medicine (Baltimore)       Date:  2022-10-14       Impact factor: 1.817

5.  Evaluation of vancomycin initial trough levels in children: A 1-year retrospective study.

Authors:  Muhammad Salem; Ahmed Khalil; Asmaa Mohamed; Ahmed Elmasoudi
Journal:  SAGE Open Med       Date:  2020-08-25

6.  Vancomycin area under the curve-guided monitoring in pediatric patients.

Authors:  Ronaldo Morales Junior; Vanessa D'Amaro Juodinis; Isabela Cristina Pinheiro de Freitas Santos; Camila Canuto Campioni; Flávia Gatto de Almeida Wirth; Livia Maria Goncalves Barbosa; Daniela Carla de Souza; Silvia Regina Cavani Jorge Santos
Journal:  Rev Bras Ter Intensiva       Date:  2022 Jan-Mar

7.  Practical approaches to improve vancomycin-related patient outcomes in pediatrics- an alternative strategy when AUC/MIC is not feasible.

Authors:  Kashif Hussain; Muhammad Sohail Salat; Shahzad Rauf; Manoj Rathi; Midhat Khan; Fizzah Naz; Wasif Ahmed Khan; Rahila Ikram; Gul Ambreen
Journal:  BMC Pharmacol Toxicol       Date:  2022-08-20       Impact factor: 2.605

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.